Produção Nacional
Revisado por pares
Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus?
2015; Wiley; Volume: 31; Issue: 5 Linguagem: Inglês
10.1002/dmrr.2639
ISSN1520-7560
AutoresKathryna F. Rodrigues, Nathalia Teixeira Pietrani, Adriana Bosco, Lirlândia P. Sousa, Cláudia N. Ferreira, Valéria C. Sandrim, Karina Braga Gomes,
Tópico(s)Kawasaki Disease and Coronary Complications
ResumoDiabetes/Metabolism Research and ReviewsVolume 31, Issue 5 p. 479-480 Letter to the Editor Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus? Kathryna F. Rodrigues, Kathryna F. Rodrigues Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorNathalia T. Pietrani, Nathalia T. Pietrani Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorAdriana A. Bosco, Adriana A. Bosco Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorLirlândia P. Sousa, Lirlândia P. Sousa Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorCláudia N. Ferreira, Cláudia N. Ferreira Colégio Técnico (COLTEC), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorValeria C. Sandrim, Valeria C. Sandrim Instituto Biociências, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, São Paulo, BrazilSearch for more papers by this authorKarina B. Gomes, Corresponding Author Karina B. Gomes orcid.org/0000-0002-6870-2063 Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Correspondence to: Karina Braga Gomes, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270-901, Brazil. E-mail: [email protected]Search for more papers by this author Kathryna F. Rodrigues, Kathryna F. Rodrigues Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorNathalia T. Pietrani, Nathalia T. Pietrani Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorAdriana A. Bosco, Adriana A. Bosco Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorLirlândia P. Sousa, Lirlândia P. Sousa Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorCláudia N. Ferreira, Cláudia N. Ferreira Colégio Técnico (COLTEC), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorValeria C. Sandrim, Valeria C. Sandrim Instituto Biociências, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, São Paulo, BrazilSearch for more papers by this authorKarina B. Gomes, Corresponding Author Karina B. Gomes orcid.org/0000-0002-6870-2063 Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Correspondence to: Karina Braga Gomes, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270-901, Brazil. E-mail: [email protected]Search for more papers by this author First published: 06 July 2015 https://doi.org/10.1002/dmrr.2639Citations: 12Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11(2): 98–107. 2Wellner M, Herse F, Janke J, et al. Endothelial cell specific molecule-1 – a newly identified protein in adipocytes. Horm Metab Res 2003; 35(4): 217–221. 3Mikkelsen ME, Shah CV, Scherpereel A, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012; 27(5): 522.e11–7. 4 American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care 2012; 35: S11–63. 5Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167(6): 3099–106. 6Janke J, Engeli S, Gorzelniak K, et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 2006; 38(1): 28–33. 7Wang X, Yang W, Luo T, Wang JM, Jing Y. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015; in press. 8Celık T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press 2015; 24(1): 55–60. 9Lee H, Choi H, Bae J. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int 2014; 86(6): 1079–1081. 10Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res 2014; 93: 92–97. 11Zhao W, Sun M, Li S, Wang Y, Liu J. Biological and clinical implications of endocan in gastric cancer. Tumour Biol 2014; 35(10): 10043–10049. Citing Literature Volume31, Issue5July 2015Pages 479-480 ReferencesRelatedInformation
Referência(s)